Compare Vital Farms Inc (VITL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vital Farms Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Vital Farms Inc trades at $13.16 (market cap $590.45M), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 206.5× Vital Farms Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| VITL | VRTX | |
|---|---|---|
Market Cap | $590.45M | $121.95B |
Sector | Consumer Staples | Health |
52-Week High | $52.41 | $529.59 |
52-Week Low | $8.28 | $366.54 |
Enterprise Value | $593.26M | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
